It was first seen in Colorado in late December, said Fu Si, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to President Biden.
“Since then it has been found in 50 jurisdictions in the United States and is probably now 20 to 30% infected in this country. And that number is growing,” Fawcett said.
He said the concern was that there had been an increase of around 0% in the UK in transitioning to this particular type and that the severity of the disease was likely to increase if infected with this type.
But the vaccine appears to be well protected against B.1.1.7 and treatments such as monoclonal antibodies also work against this particular type, Fawcett said.
Making people vaccinated faster is more important than ever, he said.
“The way we can cope with 1.1.7, which is a growing threat in our country, is two things: many people who work against this vaccine should be vaccinated as quickly and as quickly as possible with the vaccine we know. Finally, to implement the public health measures we talk about all the time … avoid masking, physical distance and especially indoor, congregation settings.
Vaccines protect against B.1.1.7 variants
U.S. The three vaccines authorized for emergency use by the Food and Drug Administration are well-protected against B1.1.7.
Johnson and Johnson’s Johnson Vaccine There is little evidence of a hand-made vaccine, however, after the B.1.1..7 began circulating its U.S. Tested in
Both Bioentech and Modern have helped coordinate multiple tests of their vaccines against variants.
Ugur Sahin and colleagues from Bioentech tested blood from 40.1 volunteers against the lab-engineered versions of the B.1.1.7 variant, using the Pfizer / Bionettech vaccine.
The virus can achieve more mutations
What worries them is if they have received more mutations by the virus. Some types are of concern doctors, including the B.1.351 variant which was first seen in South Africa and the P.1 variant which is now common in Brazil. Both have a mutation called E484K that seems to significantly suppress the body’s immune response.
“Worryingly, we have shown that the UK has multiple B..1.1.7 sequences containing E484K with preliminary evidence of transmission as well as independent acquisition.”
Some experiments suggest that b.1.351 and p.1. Forms can more easily avoid the immune response asked by the vaccine and even through some monoclonal antibody therapy the laboratory engineered immune system proteins to accelerate the immune response.
Not many experiments have been done recently using the official Johnson and Johnson vaccine, but its spread in the U.S. after the B1.7.7 spread began. Was tested in; Is already the most common type in South Africa after B.1.351; And became widespread in Brazil after P1.
When it comes to U.S. Although less effective against moderate disease than in South Africa and Brazil, it strongly advocated for people to avoid serious illness, hospitalization, and death in clinical trials.
The virus is always mutating, and some mutations have caused U.S. Has caught up with variables that are emerging, especially in California and New York. The changes they make include some changes that make the B.1.351 and P.1 variables more risky than B.1.1.7. So Fu Ki and the CDC say it makes it more important for as many people as possible to be vaccinated before they are vaccinated.
.
